Products
Xirestomig Biosimilar Bispecific Antibody (PD-L1 × 4-1BB) for Research
Cat No.: GMP-Bios-INN-1468
Anti-PDL1/CD274 therapeutic antibody (Pre-made Xirestomig biosimilar,Bispecific (G1-scFv_L2 dimer)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Xirestomig (development code ATG-101) is a bispecific antibody targeting PD-L1 (CD274). It is developed by OriCell Therapeutics and Antengene Corporation for Non-Hodgkin's lymphoma, Solid tumours in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1468-1mg | 1mg | |
| GMP-Bios-INN-1468-10mg | 10mg | |
| GMP-Bios-INN-1468-100mg | 100mg | |
| GMP-Bios-INN-1468-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Xirestomig biosimilar, Bispecific (G1-scFv_L2 dimer), Anti-PDL1/CD274;TNFRSF9/CD137/4-1BB Antibody: Anti-PD-L1/CD274/Programmed cell death 1 ligand 1/PDCD1 ligand 1 therapeutic antibody |
| INN Name | Xirestomig |
| Target | PDL1/CD274;TNFRSF9/CD137/4-1BB |
| Format | Bispecific (G1-scFv_L2 dimer) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Lambda;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | OriCell Therapeutics;Antengene Corporation |
| Conditions Approved | na |
| Conditions Active | Non-Hodgkin's lymphoma;Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
